Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final Results of the NO16968 randomized controlled phase III trial

Journal of Clinical Oncology

Volumn 33, Issue 32, 2015, Pages 3733-3740

  Schmoll, Hans Joachim ^a   Tabernero, Josep ^b   Maroun, Jean ^c   De Braud, Filippo ^d   Price, Timothy ^e   Van Cutsem, Eric ^f   Hill, Mark ^g   Hoersch, Silke ^h   Rittweger, Karen ⁱ   Haller, Daniel G ^j  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g Kent Oncology Centre   (United Kingdom)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ HOFFMANN LA ROCHE INC   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PLATINUM COMPLEX;

ADJUVANT THERAPY; ADULT; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; ADJUVANT CHEMOTHERAPY; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COLONIC NEOPLASMS; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84948409671     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.60.9107     Document Type: Article

References (23)

1. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
2. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993
3. [No authors listed]: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939-944, 1995
4. O'Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997
5. Haller DG, Catalano PJ, Macdonald JS, et al: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 23:8671-8678, 2005
6. André T, Boni C, Mounedji-Boudiaf L, et al: Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
7. Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007
8. Yothers G, O'Connell MJ, Allegra CJ, et al: Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29:3768-3774, 2011
9. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
10. Haller DG, Tabernero J, Maroun J, et al: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465-1471, 2011
11. Schmoll HJ, Cartwright T, Tabernero J, et al: Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1, 864 patients. J Clin Oncol 25:102-109, 2007
12. Sargent DJ, Patiyil S, Yothers G, et al: End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20, 898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25:4569-4574, 2007
13. de Gramont A, Hubbard J, Shi Q, et al: Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: Simulations based on the 20, 800 patient ACCENT data set. J Clin Oncol 28:460-465, 2010
14. Sargent D, Shi Q, Yothers G, et al: Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12, 676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47:990-996, 2011
15. Surveillance, Epidemiology, and End Results Program: SEER Cancer Statistics Review, 1975-2008, based on November 2010 SEER data submission. http://seer.cancer.gov/csr/1975-2008/
16. Tournigand C, Andre T, Bachet J, et al: FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial. J Clin Oncol 28:266s, 2010 (suppl; abstr 3522)
17. Maroun JA, Birnboim HC, Gorn-Hunderman I, et al: Enzyme expression profile may predict outcome in patients receiving capecitabine (Xeloda) as first-line chemotherapy for metastatic colorectal cancer (MCRC): Results of a retrospective analysis. J Clin Oncol 22:14s, 2004 (suppl; abstr 9652)
18. Schüller J, Cassidy J, Dumont E, et al: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297, 2000
19. André T, Quinaux E, Louvet C, et al: Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: Final results of GERCOR C96.1. J Clin Oncol 25:3732-3738, 2007
20. Twelves C, Wong A, Nowacki MP, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704, 2005
21. Köhne CH, Bedenne L, Carrato A, et al: A randomised phase III intergroup trial comparing high-dose infusional fluorouracil with or without folinic acid with standard bolus fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colon Cancer 2 study. Eur J Cancer 49:1868-1875, 2013
22. Schmoll HJ, Van Cutsem E, Stein A, et al: ESMO consensus guidelines for management of patients with colon and rectal cancer: A personalized approach to clinical decision making. Ann Oncol 23:2479-2516, 2012
23. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon cancer, version 2, 2015. http://www.nccn.org/professionals/physician-gls/pdf/colon. pdf.